sur GENOWAY (EPA:ALGEN)
GenOway Announces the Publication of its 2025 Annual Revenue
On January 19, 2026, genOway, a specialist in predictive preclinical solutions, announced that its 2025 annual revenue will be published on January 26, 2026, after the close of Euronext markets. Listed on Euronext Growth, genOway contributes to the safe and efficient selection of drug candidates by its clients.
On this occasion, a webinar will be held at 6:15 p.m. for shareholders and individual investors. Alexandre Fraichard, CEO, will discuss the company's activities for 2025 and its strategic outlook. This outlook is strengthened by the recent acquisition of assets in OMICS and artificial intelligence.
Registration for the webinar is open until the day of the event. Registered participants will receive instructions on how to participate. Questions can be sent to genoway@actus.fr.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENOWAY